Scinai ends PC111 arrangements, shifts focus to NanoAb and CDMO business

Scinai Immunotherapeutics announced on September 8, 2026 that it has concluded its option and license arrangements with PinCell S.r.l. related to PC111. Following discussions between Scinai and PinCell regarding a possible extension, no further agreement was reached, and the applicable option conditions expired on August 31, 2026, with the Option Agreement and related License Agreement terminating in accordance with their terms.¹

The company said the outcome was not driven by any new negative scientific finding regarding PC111.¹ CEO Amir Reichman said advancing any preclinical asset through meaningful de-risking requires substantial capital and time, and in the absence of secured grant funding for PC111, continuing involvement would have required additional investment before there was visibility on non-dilutive financing.¹

Scinai will now direct resources to its NanoAb platform, which uses VHH antibody fragments to support the development of mono-, bi- and multi-specific therapeutic formats for inflammatory and immune-mediated diseases.¹ Within that platform, the company is advancing two complementary IL-17 programs, with its intradermal IL-17 program for psoriasis the subject of an application under Poland's FENG program for approximately €12 million in grant financing to support development from preclinical stage through first-in-human readiness.¹

On the CDMO side, Committed Customer Orders totaled approximately $3.1 million as of August 16, 2026 across the Jerusalem and Yavne facilities, with the company continuing to pursue approximately $5 million of CDMO revenue for 2026.¹ Scinai also disclosed that it has commenced substantive activities on an expanded clinical manufacturing and CMC program for a U.S.-based biopharmaceutical customer, intended to support a planned U.S. regulatory submission and subsequent Phase III development.¹